Literature DB >> 11713134

Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography.

S Krüger1, P Haage, R Hoffmann, C Breuer, A Bücker, P Hanrath, R W Günther.   

Abstract

BACKGROUND: Pulmonary magnetic resonance angiography (PMRA) has been proven to be accurate for the diagnosis of suspected acute or chronic pulmonary embolism (PE). Only limited data exist on the reliability of PMRA for the diagnosis of acute and chronic pulmonary artery hypertension (PAH). The aim of this study was to determine the accuracy of PMRA in the differentiation between patients suffering from PAH of varying etiologies.
METHODS: Fifty patients (21 women; mean [+/- SD] age, 52 +/- 16 years) were examined with gadolinium-enhanced PMRA for the evaluation of pulmonary artery (PA) disease. The diagnosis of PAH (ie, systolic PA pressure of > 35 mm Hg) was determined by Doppler echocardiography. The criteria for the diagnosis of chronic PAH by PMRA were dilated central PAs (diameter > 28 mm) and abnormal proximal-to-distal tapering of the PAs. The diagnostic criterion for acute and chronic PE was the presence of an intravascular filling defect.
RESULTS: Chronic PAH was present in 18 patients, which was correctly identified by PMRA in 16 patients (sensitivity, 89%). All patients without PAH had normal findings on PMRA (specificity, 100%). Only 1 of 18 patients with normal findings on PMRA showed moderate chronic PAH (negative predictive value, 94%). PAH due to acute/subacute pulmonary thromboembolism (15 patients) was identified in all patients (sensitivity, 100%). Acute PAH was differentiated from chronic PAH in all cases by the detection of intravascular filling defects and the lack of abnormal proximal-to-distal tapering of PAs.
CONCLUSIONS: PMRA is a promising noninvasive imaging modality for the identification of patients with acute or chronic PAH. This technique should be considered a sensitive and highly specific screening tool for suspected chronic PAH.

Entities:  

Mesh:

Year:  2001        PMID: 11713134     DOI: 10.1378/chest.120.5.1556

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Pulmonary arterial hypertension: an imaging review comparing MR pulmonary angiography and perfusion with multidetector CT angiography.

Authors:  F P Junqueira; C M A O Lima; A C Coutinho; D B Parente; L K Bittencourt; L G P Bessa; R C Domingues; E Marchiori
Journal:  Br J Radiol       Date:  2012-08-29       Impact factor: 3.039

2.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

Review 3.  Pulmonary thromboembolism in children.

Authors:  Paul S Babyn; Harpal K Gahunia; Patricia Massicotte
Journal:  Pediatr Radiol       Date:  2005-01-06

4.  Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham Heart Study.

Authors:  Quynh A Truong; Joseph M Massaro; Ian S Rogers; Amir A Mahabadi; Matthias F Kriegel; Caroline S Fox; Christopher J O'Donnell; Udo Hoffmann
Journal:  Circ Cardiovasc Imaging       Date:  2011-12-16       Impact factor: 7.792

5.  Prevalence of pulmonary hypertension associated with severe acute respiratory distress syndrome: predictive value of computed tomography.

Authors:  Martin Beiderlinden; Hilmar Kuehl; Tanja Boes; Jürgen Peters
Journal:  Intensive Care Med       Date:  2006-04-14       Impact factor: 17.440

Review 6.  [Chronic pulmonary embolism--radiological imaging and differential diagnosis].

Authors:  E Coppenrath; P Herzog; U Attenberger; M Reiser
Journal:  Radiologe       Date:  2007-08       Impact factor: 0.635

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.